JMP Securities Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $49
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst David Turkaly maintains a Market Outperform rating on Integra Lifesciences (IART) but lowers the price target from $55 to $49.

February 29, 2024 | 7:22 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JMP Securities maintains a Market Outperform rating on Integra Lifesciences but lowers the price target from $55 to $49.
While the reduction in price target could suggest a tempered outlook on the stock's potential upside, the maintenance of a Market Outperform rating indicates a continued positive view on the company's fundamentals. This mixed signal might lead to a neutral short-term impact on the stock price as investors weigh the lowered price target against the analyst's ongoing confidence in the company.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100